Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZENITH Phase 3 zilebesiran outcomes trial in uncontrolled hypertension with cardiovascular disease or high cardiovascular risk
2025-522960-34-00Phase 3Authorised
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Feb 2026
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 35
01
Overview
Phase 3, randomised, double-blind trial in hypertension (HTN) comparing Zilebesiran + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to first occurrence of major adverse cardiovascular events or heart failure event. Planned start Feb 2026; status: authorised.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on 2025-522960-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522960-34-00.